SAFETY DATA SHEET

Levamisole / Oxyclozanide Formulation

Version 1.5  Revision Date: 27.08.2021  SDS Number: 5360105-00006  Date of last issue: 09.04.2021  Date of first issue: 19.12.2019

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Levamisole / Oxyclozanide Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Veterinary product

1.3 Details of the supplier of the safety data sheet
   Company : MSD
   20 Spartan Road
   1619 Spartan, South Africa
   Telephone : +27119239300
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   +1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
   Classification (REGULATION (EC) No 1272/2008)
   Reproductive toxicity, Category 2
   Long-term (chronic) aquatic hazard, Category 2
   H361d: Suspected of damaging the unborn child.
   H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements
   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms :
   Signal word : Warning
   Hazard statements : H361d Suspected of damaging the unborn child. H411 Toxic to aquatic life with long lasting effects.
   Precautionary statements : Prevention:
   P201 Obtain special instructions before use.
   P273 Avoid release to the environment.
   P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P308 + P313  IF exposed or concerned: Get medical advice/attention.
P391  Collect spillage.

Storage:
P405  Store locked up.

Hazardous components which must be listed on the label:
oxyclozanide

2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>oxyclozanide</td>
<td>2277-92-1</td>
<td>218-904-0</td>
<td></td>
<td></td>
<td>Repr. 2; H361d STOT SE 2; H371 (Central nervous system) STOT RE 2; H373 (Brain, Liver) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1</td>
<td>&gt;= 3 - &lt; 10</td>
</tr>
<tr>
<td></td>
<td>levamisole hydrochloride</td>
<td>16595-80-5</td>
<td>240-654-6</td>
<td></td>
<td></td>
<td>Acute Tox. 3; H301 Repr. 2; H361d STOT RE 2; H373 (Blood, Testis) Aquatic Chronic 3; H412</td>
<td>&gt;= 1 - &lt; 2,5</td>
</tr>
<tr>
<td></td>
<td>Citric acid</td>
<td>77-92-9</td>
<td>201-069-1</td>
<td></td>
<td></td>
<td>Eye Irrit. 2; H319</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.
SECTION 4: First aid measures

4.1 Description of first aid measures

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks: Suspected of damaging the unborn child.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.
SAFETY DATA SHEET

Levamisole / Oxyclonanide Formulation

Version 1.5  Revision Date: 27.08.2021  SDS Number: 5360105-00006  Date of last issue: 09.04.2021
Date of first issue: 19.12.2019

Hazardous combustion products:
- Carbon oxides
- Silicon oxides
- Metal oxides
- Chlorine compounds
- Nitrogen oxides (NOx)

5.3 Advice for firefighters
Special protective equipment for firefighters:
In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures
Personal precautions:
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions
Environmental precautions:
Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up
Methods for cleaning up:
Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.
SAFETY DATA SHEET

Levamisole / Oxyclonanide Formulation

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe mist or vapours.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Wash skin thoroughly after handling.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Do not eat, drink or smoke when using this product.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers: Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.

Advice on common storage:
- Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>oxyclozanide</td>
<td>2277-92-1</td>
<td>TWA</td>
<td>0.4 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>400 mg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>levamisole hydrochloride</td>
<td>16595-80-5</td>
<td>TWA</td>
<td>20 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: Skin Wipe limit 200 µg/100 cm² Internal
Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citric acid</td>
<td>Fresh water</td>
<td>0.44 mg/l</td>
</tr>
<tr>
<td></td>
<td>Marine water</td>
<td>0.044 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>1000 mg/l</td>
</tr>
<tr>
<td>Fresh water sediment</td>
<td></td>
<td>34.6 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>Marine sediment</td>
<td></td>
<td>3.46 mg/kg dry weight (d.w.)</td>
</tr>
<tr>
<td>Soil</td>
<td></td>
<td>33.1 mg/kg dry weight (d.w.)</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment
Eye protection: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection
Material: Chemical-resistant gloves
Remarks: Consider double gloving.

Skin and body protection: Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties
Appearance: liquid
Colour: No data available
Odour: No data available
Odour Threshold: No data available
SAFETY DATA SHEET

Levamisole / Oxyclozanic Formulation

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.
10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: None known.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:
oxyclozanide:
Acute oral toxicity: LD50 (Rat): 3.519 mg/kg
Target Organs: Central nervous system

Acute toxicity (other routes of administration): LDLo (sheep): 10 mg/kg
Application Route: Intravenous

levamisole hydrochloride:
Acute oral toxicity: LD50 (Rat): 180 mg/kg
LD50 (Mouse): 223 mg/kg
LD50 (Rabbit): 458 mg/kg

Acute inhalation toxicity: Remarks: No data available

Acute dermal toxicity: Remarks: No data available

Citric acid:
SAFETY DATA SHEET

Levamisole / Oxyclozanide Formulation

Acute oral toxicity: LD50 (Mouse): 5.400 mg/kg
Acute dermal toxicity: LD50 (Rat): > 2.000 mg/kg
   Method: OECD Test Guideline 402
   Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation
Not classified based on available information.

Components:

Oxyclozanide:
Remarks: Not classified due to lack of data.

Levamisole hydrochloride:
Remarks: No data available

Citric acid:
Species: Rabbit
Method: OECD Test Guideline 404
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Oxyclozanide:
Remarks: Not classified due to lack of data.

Levamisole hydrochloride:
Remarks: No data available

Citric acid:
Species: Rabbit
Method: OECD Test Guideline 405
Result: Irritation to eyes, reversing within 21 days

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Oxyclozanide:
Exposure routes: Dermal
### SAFETY DATA SHEET

**Levamisole / Oxyclozanide Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.5</td>
<td>27.08.2021</td>
<td>5360105-00006</td>
<td>09.04.2021</td>
<td>19.12.2019</td>
</tr>
</tbody>
</table>

Remarks : Not classified due to lack of data.

**levamisole hydrochloride:**
Remarks : No data available

Germ cell mutagenicity
Not classified based on available information.

**Components:**

**Oxyclozanide:**

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Bacterial reverse mutation assay (AMES) Result: negative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive</td>
</tr>
<tr>
<td></td>
<td>Test Type: Mouse Lymphoma Result: positive</td>
</tr>
</tbody>
</table>

Genotoxicity in vivo : Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

**levamisole hydrochloride:**

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Bacterial reverse mutation assay (AMES) Result: negative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Test Type: Chromosome aberration test in vitro Result: negative</td>
</tr>
</tbody>
</table>

**Citric acid:**

<table>
<thead>
<tr>
<th>Genotoxicity in vitro</th>
<th>Test Type: Bacterial reverse mutation assay (AMES) Result: negative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Test Type: in vitro micronucleus test Result: positive</td>
</tr>
<tr>
<td></td>
<td>Test Type: Bacterial reverse mutation assay (AMES) Result: negative</td>
</tr>
</tbody>
</table>
Genotoxicity in vivo:
- Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
- Species: Rat
- Application Route: Ingestion
- Result: negative

Carcinogenicity
Not classified based on available information.

Components:

oxyclozanide:
- Remarks: Not classified due to lack of data.

levamisole hydrochloride:
- Species: Mouse
- Application Route: Oral
- Exposure time: 2 Years
- NOAEL: 80 mg/kg body weight
- Remarks: No significant adverse effects were reported

Species: Rat
- Application Route: Oral
- Exposure time: 2 Years
- NOAEL: 40 mg/kg body weight
- Remarks: No significant adverse effects were reported

Reproductive toxicity
Suspected of damaging the unborn child.

Components:

oxyclozanide:
- Effects on fertility: Test Type: Two-generation reproduction toxicity study
  - Species: Rat, male and female
  - Application Route: Oral
  - General Toxicity - Parent: NOAEL: 25 - 35 mg/kg body weight
  - Symptoms: Reduced body weight, No effects on embryofetal and postnatal development
  - Result: No effects on fertility

  Test Type: Two-generation reproduction toxicity study
  - Species: Rat
  - Application Route: Oral
  - General Toxicity - Parent: LOAEL: 75 - 100 mg/kg body weight
  - Symptoms: Reduced body weight, No effects on embryofetal and postnatal development
  - Result: No effects on fertility

  Test Type: Two-generation reproduction toxicity study
  - Species: Rat
  - Application Route: Oral
  - Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight

Version: 1.5
Revision Date: 27.08.2021
SDS Number: 5360105-00006
Date of last issue: 09.04.2021
Date of first issue: 19.12.2019
SAFETY DATA SHEET

Levamisole / Oxyclozanide Formulation

weight
Result: No fetotoxicity, No teratogenic effects

Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Oral
General Toxicity - Parent: LOAEL: 80 - 160 mg/kg body weight
Result: No fetotoxicity, No teratogenic effects, No effects on fertility

Effects on foetal development: Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 200 mg/kg body weight
Result: No fetotoxicity, No teratogenic effects

Test Type: Development
Species: Rat
Application Route: Oral
General Toxicity Maternal: LOAEL: 100 mg/kg body weight
Result: No fetotoxicity, No teratogenic effects

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 32 mg/kg body weight
Result: Fetotoxicity, Skeletal malformations

Reproductive toxicity - Assessment: Suspected of damaging the unborn child.

levamisole hydrochloride:

Effects on fertility: Test Type: Three-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Result: No significant adverse effects were reported

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 20 mg/kg body weight
Result: Fetotoxicity

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 40 mg/kg body weight
Result: Fetotoxicity

Reproductive toxicity - Assessment: Some evidence of adverse effects on development, based on animal experiments.

Citric acid:

Effects on foetal development: Test Type: One-generation reproduction toxicity study
SAFETY DATA SHEET

Levamisole / Oxyclozanide Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.5</td>
<td>27.08.2021</td>
<td>5360105-00006</td>
<td>09.04.2021</td>
<td>19.12.2019</td>
</tr>
</tbody>
</table>

Species: Rat
Application Route: Ingestion
Result: negative

**STOT - single exposure**
Not classified based on available information.

**Components:**

**oxyclozanide:**
- Exposure routes: Oral
- Target Organs: Central nervous system
- Assessment: May cause damage to organs.

**levamisole hydrochloride:**
- Target Organs: Blood, Testis
- Assessment: May cause damage to organs through prolonged or repeated exposure.

**STOT - repeated exposure**
Not classified based on available information.

**Components:**

**oxyclozanide:**
- Target Organs: Brain, Liver
- Assessment: May cause damage to organs through prolonged or repeated exposure.

**levamisole hydrochloride:**
- Target Organs: Blood, Testis
- Assessment: May cause damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**oxyclozanide:**
- Species: Rat
- NOAEL: 9 mg/kg
- LOAEL: 44,5 mg/kg
- Application Route: Oral
- Exposure time: 3 Months
- Target Organs: Brain, Liver, spleen, Adrenal gland
- Symptoms: Liver effects

- Species: Dog
- NOAEL: 5 mg/kg
- LOAEL: 25 mg/kg
- Application Route: Oral
- Exposure time: 3 Months
- Target Organs: Brain, Liver
- Symptoms: blood effects, alteration in liver enzymes

**levamisole hydrochloride:**
- Species: Rat
- NOAEL: 2,5 mg/kg
Application Route: Oral
Exposure time: 18 Months
Target Organs: Testis

Species: Dog
LOAEL: 20 mg/kg
Application Route: Oral
Exposure time: 18 Months
Target Organs: Blood

Species: Dog
LOAEL: 40 mg/kg
Application Route: Oral
Exposure time: 3 Months

Citric acid:
Species: Rat
NOAEL: 4,000 mg/kg
LOAEL: 8,000 mg/kg
Application Route: Ingestion
Exposure time: 10 Days

Aspiration toxicity
Not classified based on available information.

Components:
oxyclozanide:
Not applicable

Experience with human exposure

Components:
oxyclozanide:
Ingestion: Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

levamisole hydrochloride:
Ingestion: Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension

SECTION 12: Ecological information

12.1 Toxicity

Components:
oxyclozanide:
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 0.69 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

M-Factor (Acute aquatic tox-:
: 1
SAFETY DATA SHEET

Levamisole / Oxyclozanide Formulation

Version 1.5
Revision Date: 27.08.2021
SDS Number: 5360105-00006
Date of last issue: 09.04.2021
Date of first issue: 19.12.2019

M-Factor (Chronic aquatic toxicity):
levamisole hydrochloride:
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 64 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Citric acid:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 1.535 mg/l
Exposure time: 24 h

12.2 Persistence and degradability

Components:
oxyclozanide:
Stability in water: Hydrolysis: 50 % (156 d)
Method: OECD Test Guideline 111

Citric acid:
Biodegradability: Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

12.3 Bioaccumulative potential

Components:
oxyclozanide:
Partition coefficient: n-octanol/water: log Pow: 3.99
pH: 7
Method: OECD Test Guideline 107

Citric acid:
Partition coefficient: n-octanol/water: log Pow: -1.72

12.4 Mobility in soil

Components:
oxyclozanide:
Distribution among environmental compartments: log Koc: 4.83
Method: OECD Test Guideline 106

12.5 Results of PBT and vPvB assessment

Product:
Assessment: This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Other adverse effects

Product:
Endocrine disrupting potential: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
ADN: UN 3082
ADR: UN 3082
RID: UN 3082
IMDG: UN 3082
IATA: UN 3082

14.2 UN proper shipping name
ADN: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxyclozanide)
ADR: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxyclozanide)
RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxyclozanide)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxyclozanide)

IATA : Environmentally hazardous substance, liquid, n.o.s. (oxyclozanide)

### 14.3 Transport hazard class(es)

- **ADN** : 9
- **ADR** : 9
- **RID** : 9
- **IMDG** : 9
- **IATA** : 9

### 14.4 Packing group

**ADN**
- Packing group : III
- Classification Code : M6
- Hazard Identification Number : 90
- Labels : 9

**ADR**
- Packing group : III
- Classification Code : M6
- Hazard Identification Number : 90
- Labels : 9
- Tunnel restriction code : (-)

**RID**
- Packing group : III
- Classification Code : M6
- Hazard Identification Number : 90
- Labels : 9

**IMDG**
- Packing group : III
- Labels : 9
- EmS Code : F-A, S-F

**IATA (Cargo)**
- Packing instruction (cargo aircraft) : 964
- Packing instruction (LQ) : Y964
- Packing group : III
- Labels : Miscellaneous

**IATA (Passenger)**
- Packing instruction (passenger aircraft) : 964
- Packing instruction (LQ) : Y964
- Packing group : III
14.5 Environmental hazards

<table>
<thead>
<tr>
<th>ADN</th>
<th>Environmentally hazardous</th>
<th>yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>Environmentally hazardous</td>
<td>yes</td>
</tr>
<tr>
<td>RID</td>
<td>Environmentally hazardous</td>
<td>yes</td>
</tr>
<tr>
<td>IMDG</td>
<td>Marine pollutant</td>
<td>yes</td>
</tr>
<tr>
<td>IATA (Passenger)</td>
<td>Environmentally hazardous</td>
<td>yes</td>
</tr>
<tr>
<td>IATA (Cargo)</td>
<td>Environmentally hazardous</td>
<td>yes</td>
</tr>
</tbody>
</table>

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code

Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

<table>
<thead>
<tr>
<th>AICS</th>
<th>not determined</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSL</td>
<td>not determined</td>
</tr>
<tr>
<td>IECSC</td>
<td>not determined</td>
</tr>
</tbody>
</table>

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H301: Toxic if swallowed.
H319: Causes serious eye irritation.
H361d: Suspected of damaging the unborn child.
H371: May cause damage to organs if swallowed.
Levamisole / Oxyclozanide Formulation

Full text of other abbreviations

Acute Tox.: Acute toxicity
Aquatic Acute: Short-term (acute) aquatic hazard
Aquatic Chronic: Long-term (chronic) aquatic hazard
Eye Irrit.: Eye irritation
Repr.: Reproductive toxicity
STOT RE: Specific target organ toxicity - repeated exposure
STOT SE: Specific target organ toxicity - single exposure

Further information

Classification of the mixture:  
Repr. 2          H361d         Calculation method
Aquatic Chronic 2 H411         Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.